Matches in Nanopublications for { ?s ?p "[More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- NP697630.RAnYrP-p8jnIuV_7Spv1mO7nYWvibimOeivydIEK4fMWE130_assertion description "[More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697630.RAnYrP-p8jnIuV_7Spv1mO7nYWvibimOeivydIEK4fMWE130_provenance.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion description "[More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_provenance.
- NP374624.RAR2BkvxxXg-gH1quqOLZaB6_IVcBT2h1govAeSLKQJEc130_assertion description "[More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP374624.RAR2BkvxxXg-gH1quqOLZaB6_IVcBT2h1govAeSLKQJEc130_provenance.